Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...
Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...
Shenzhen-based QuantumPharm Inc., trading under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...
US-based Danaher Corporation (NYSE: DHR), a leading science and tech services provider, has officially launched...
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
The State Administration for Market Regulation (SAMR) in China has given its approval in principle...
On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...
On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,...
On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...
The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...
UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...
The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...
China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...
Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...
Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...